Drug Profile
Research programme: controlled-release ophthalmic therapeutics - Kiora Pharmaceuticals
Alternative Names: CMHA-S films - Kiora Pharmaceuticals; Controlled-release antibacterial ophthalmic therapeutics - Kiora Pharmaceuticals; JDE 001; JDE-004; JDE-005; JDE-006; Recombinant hGH - Kiora Pharmaceuticals; Recombinant human growth hormone - Kiora Pharmaceuticals; Somatropin - Kiora PharmaceuticalsLatest Information Update: 15 Nov 2021
Price :
$50
*
At a glance
- Originator Jade Therapeutics
- Developer Kiora Pharmaceuticals
- Class Antibacterials; Eye disorder therapies; Growth hormones
- Mechanism of Action Somatostatin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Corneal disorders; Corneal injuries; Dry eyes; Infectious keratitis
Most Recent Events
- 08 Nov 2021 EyeGate Pharma is now called Kiora Pharmaceuticals
- 28 May 2020 No recent reports of development identified for preclinical development in Dry-eyes in USA (Ophthalmic, Controlled release)
- 31 Jul 2019 BioTime is now called Lineage Cell Therapeutics